Randomized, blinded, active-controlled Phase II clinical trial of ReCOV on healthy subjects who have received primary vaccination with two doses of an inactivated COVID-19 vaccine compared with Pfizer's mRNA vaccine COMIRNATY
Latest Information Update: 26 Dec 2022
At a glance
- Drugs Recombinant two component COVID 19 vaccine Jiangsu Rec Biotechnology (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 25 Dec 2022 Results published in the Jiangsu Recbio Media Release
- 18 Aug 2022 According to Jiangsu Recbio Technology media release, enrollment and dosing has been completed in this trial in around two weeks from the receipt of clinical trial approval .
- 18 Aug 2022 Status changed from planning to active, no longer recruiting, according to a Jiangsu Recbio Technology media release.